Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase Ⅰ Clinical Data At ESC Congress 2024
Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA.
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9
...